Abstract:Pharmacological and cellular treatment of cancer is changing dramatically with benefits for patient outcome and comfort, but also with new toxicity profiles. The majority of adverse events can be classified as mild or moderate, but severe and life-threatening complications requiring ICU admission also occur. This review will focus on pathophysiology, symptoms, and management of these events based on the available literature.While standard antineoplastic therapy is associated with immunosuppression and infections, some of the recent approaches induce overwhelming inflammation and autoimmunity. Cytokine-release syndrome (CRS) describes a complex of symptoms including fever, hypotension, and skin reactions as well as lab abnormalities. CRS may occur after the infusion of monoclonal or bispecific antibodies (MABs, BABs) targeting immune effectors and tumor cells and is a major concern in recipients of chimeric antigen receptor (CAR) modified T lymphocytes as well. BAB and CAR T-cell treatment may also be compromised by central nervous system (CNS) toxicities such as encephalopathy, cerebellar alteration, disturbed consciousness, or seizures. While CRS is known to be induced by exceedingly high levels of inflammatory cytokines, the pathophysiology of CNS events is still unclear. Treatment with antibodies against inhibiting immune checkpoints can lead to immune-related adverse events (IRAEs); colitis, diarrhea, and endocrine disorders are often the cause for ICU admissions.Respiratory distress is the main reason for ICU treatment in cancer patients and is attributable to infectious agents in most cases. In addition, some of the new drugs are reported to cause non-infectious lung complications. While drug-induced interstitial pneumonitis was observed in a substantial number of patients treated with phosphoinositol-3-kinase inhibitors, IRAEs may also affect the lungs.Inhibitors of angiogenetic pathways have increased the antineoplastic portfolio. However, vessel formation is also essential for regeneration and tissue repair. Therefore, severe vascular side effects, including thromboembolic events, gastrointestinal bleeding or perforation, hypertension, and congestive heart failure, compromise antitumor efficacy.The limited knowledge of the pathophysiology and management of life-threatening complications relating to new cancer drugs presents a need to provide ICU staff, oncologists, and organ specialists with evidence-based algorithms.

Supportive care in the era of immunotherapies for advanced non-small-cell lung cancer

Monitoring and Management of Immune-Related Adverse Events Associated With Programmed Cell Death Protein-1 Axis Inhibitors in Lung Cancer

Clinical management of immune-related adverse events following immunotherapy treatment in patients with non-small cell lung cancer

Adverse Events of Oncologic Immunotherapy and Their Management

Treatment of the Immune-Related Adverse Effects of Immune Checkpoint Inhibitors: A Review

Beyond Chemoimmunotherapy in Advanced Non-Small Cell Lung Cancer: New Frontiers, New Challenges

Updates and emerging trends in the management of immune-related adverse events associated with immune checkpoint inhibitor therapy

Immune-related adverse events with immune checkpoint blockade: a comprehensive review

Immune checkpoint inhibitors in non-small cell lung cancer: from current perspectives to future treatments-a systematic review

New drugs, new toxicities: severe side effects of modern targeted and immunotherapy of cancer and their management

Immune-Related Adverse Events in Patients with Lung Cancer

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline.

Toxicity profiles of immunotherapy

The Landscape of Immunotherapy in Advanced NSCLC: Driving Beyond PD-1/PD-L1 Inhibitors (CTLA-4, LAG3, IDO, OX40, TIGIT, Vaccines)

Management of Pulmonary Toxicities Associated with Systemic Therapy in Non Small Cell Lung Cancer

Toxicity of immunotherapy combinations with chemotherapy across tumor indications: Current knowledge and practical recommendations

Toxicities of Immunotherapy for Small Cell Lung Cancer

Immunotherapy: From Advanced NSCLC to Early Stages, an Evolving Concept

Immunotherapy in Lung Cancer: A New Age in Cancer Treatment

Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune-related adverse events: pulmonary toxicity

Potentially fatal complications of new systemic anticancer therapies: pearls and pitfalls in their initial management